Evidence map›Paper›PMID 31577934›Full record

ArticleCell metabolism2019

Dietary Sugars Alter Hepatic Fatty Acid Oxidation via Transcriptional and Post-translational Modifications of Mitochondrial Proteins.

Samir Softic, Jesse G Meyer, Guo-Xiao Wang, Manoj K Gupta, Thiago M Batista, Hans P M M Lauritzen, Shiho Fujisaka, Dolors Serra, Laura Herrero, Jennifer Willoughby and 7 more

Open access · greenAbstract read
In one paragraph

Article in Cell metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 1 pooled it
16.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 1 synthesis or guideline pooled it, 224 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. ChREBP-β Exacerbates Renal Tubular Disorders Caused by Fructose via ATF4.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Epigenetics of Childhood Obesity.Hormone research in paediatrics · 2026
    Review
  17. Review
  18. Frontiers in pharmacology · 2026
    Article
  19. Article
  20. Guidelines for diet-induced models of cardiometabolic syndrome.American journal of physiology. Heart and circulatory physiology · 2025
    Review

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

Samir SofticSection on Integrative Physiology and Metabolism, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA 02115, USA; Division of Gastroenterology, Hepatology, Nutrition, Department of Pediatrics, University of Kentucky College of Medicine and Kentucky Children's Hospital, Lexington, KY 40506, USA. Electronic address: samir.softic@uky.edu.
Jesse G MeyerChemistry & Mass Spectrometry, Buck Institute for Research on Aging, Novato, CA 94945, USA.
Guo-Xiao WangSection on Integrative Physiology and Metabolism, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Manoj K GuptaIslet Cell and Regenerative Medicine, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Thiago M BatistaSection on Integrative Physiology and Metabolism, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Hans P M M LauritzenSection on Integrative Physiology and Metabolism, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Shiho FujisakaSection on Integrative Physiology and Metabolism, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; First Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
Dolors SerraSchool of Pharmacy, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Barcelona 08028, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid 28029, Spain.
Laura HerreroSchool of Pharmacy, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Barcelona 08028, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid 28029, Spain.
Jennifer WilloughbyAlnylam Pharmaceuticals Inc., Cambridge, MA 021428, USA.
Kevin FitzgeraldAlnylam Pharmaceuticals Inc., Cambridge, MA 021428, USA.
Olga IlkayevaSarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Departments of Pharmacology & Cancer Biology and Medicine, Duke University Medical Center, Durham, NC 27701, USA.
Christopher B NewgardSarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Departments of Pharmacology & Cancer Biology and Medicine, Duke University Medical Center, Durham, NC 27701, USA.
Bradford W GibsonChemistry & Mass Spectrometry, Buck Institute for Research on Aging, Novato, CA 94945, USA.
Birgit SchillingChemistry & Mass Spectrometry, Buck Institute for Research on Aging, Novato, CA 94945, USA.
David E CohenDivision of Gastroenterology and Hepatology, Weill Cornell Medical College New York, New York, NY 10021, USA.
C Ronald KahnSection on Integrative Physiology and Metabolism, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Electronic address: c.ronald.kahn@joslin.harvard.edu.
Joslin Diabetes Center · USBuck Institute for Research on Aging · USAlnylam Pharmaceuticals (United States) · USDuke University · USInstituto de Salud Carlos III · ESBoston Children's Hospital · USCornell University · US

Funding

Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHRISTOPHER P DUGGAN · 1994 to 2026
$31.6M
REVERSIBLE MITOCHONDRIAL PROTEIN ACETYLATION AND METABOLIC REGULATIONR24DK085610 · NIDDK · J. DAVID GLADSTONE INSTITUTES · PI VERDIN, ERIC M. · 2010 to 2019
$16.0M
Training in Basic Research on Aging and Age-Related DiseaseT32AG000266 · NIA · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Lisa M Ellerby · 1998 to 2026
$13.8M
INSULIN RECEPTOR STRUCTURE AND TURNOVERR37DK031036 · NIDDK · JOSLIN DIABETES CENTER · PI KAHN, C RONALD · 2000 to 2019
$12.9M
Insulin Receptor Substrates and Insulin ActionR01DK033201 · NIDDK · JOSLIN DIABETES CENTER · PI KAHN, C RONALD · 1986 to 2016
$10.6M
Phospholipid-Mediated Metabolic Control in the Pathogenesis of NAFLDR01DK056626 · NIDDK · YESHIVA UNIVERSITY · PI COHEN, DAVID E. · 2000 to 2024
$10.3M
Them1-Mediated Metabolic Regulation and Pathogenic Role in NAFLDR01DK103046 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI DAVID E. COHEN, Susan J Hagen · 2015 to 2026
$7.6M
Regulation of Hepatic Lipid and Glucose Metabolism by PC-TP/StarD2R37DK048873 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI COHEN, DAVID E. · 2012 to 2021
$5.5M
The Insulin Receptor and Its Signaling MechanismsR01DK031036 · NIDDK · JOSLIN DIABETES CENTER · PI C RONALD KAHN · 1986 to 2026
$4.2M
Interaction between genes, environment, the microbiome and metabolome in type 2 diabetes and metabolic syndromeR01DK121967 · NIDDK · JOSLIN DIABETES CENTER · PI KAHN, C RONALD · 2020 to 2024
$2.7M
TripleTOF 5600 High Resolution Mass SpectrometerS10OD016281 · OD · BUCK INSTITUTE FOR RESEARCH ON AGING · PI GIBSON, BRADFORD WAYNE · 2013 to 2013
$597k
NIA NIH HHS T32 AG000266NICHD NIH HHS K12 HD000850NIDDK NIH HHS P30 DK040561NIDDK NIH HHS R01 DK031036NIDDK NIH HHS R01 DK033201NIDDK NIH HHS R01 DK056626NIDDK NIH HHS R01 DK103046NIDDK NIH HHS R01 DK121967NIDDK NIH HHS R24 DK085610NIDDK NIH HHS R37 DK031036NIDDK NIH HHS R37 DK048873NIH HHS S10 OD016281
6 · The paper itself

Abstract

Dietary sugars, fructose and glucose, promote hepatic de novo lipogenesis and modify the effects of a high-fat diet (HFD) on the development of insulin resistance. Here, we show that fructose and glucose supplementation of an HFD exert divergent effects on hepatic mitochondrial function and fatty acid oxidation. This is mediated via three different nodes of regulation, including differential effects on malonyl-CoA levels, effects on mitochondrial size/protein abundance, and acetylation of mitochondrial proteins. HFD- and HFD plus fructose-fed mice have decreased CTP1a activity, the rate-limiting enzyme of fatty acid oxidation, whereas knockdown of fructose metabolism increases CPT1a and its acylcarnitine products. Furthermore, fructose-supplemented HFD leads to increased acetylation of ACADL and CPT1a, which is associated with decreased fat metabolism. In summary, dietary fructose, but not glucose, supplementation of HFD impairs mitochondrial size, function, and protein acetylation, resulting in decreased fatty acid oxidation and development of metabolic dysregulation.

Indexed as

Mitochondrial ProteinsAnimalsCell LineDietary SugarsDiet, High-FatFatty AcidsFructoseGlucoseLipogenesisLiverMaleMiceMice, Inbred C57BLMitochondriaObesityProtein Processing, Post-TranslationalDietary SugarsFatty AcidsFructoseGlucoseMitochondrial Proteinsacetylationfatty acid oxidationfatty liver diseasefructoseglucoseketohexokinasemass spectrometrymitochondriaobesitysugar

Identifiers

PMID31577934
PMCPMC7816129
OpenAlexW2977959633

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.